A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Trial Profile

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 27 Jul 2017 According to a celgene corporation media release, company anticipates completion of enrollment in second half of 2017.
    • 16 Jun 2017 Planned number of patients changed from 32 to 43.
    • 16 Jun 2017 Planned End Date changed from 15 May 2019 to 15 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top